About

Founded

2015

Headquarters

Chicago, Illinois

Industry

Healthcare, Artificial Intelligence (AI)

Company Description

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets.

Quick Links

Website Jobs

Funding

Total Raised

$1.3 billion

Valuation

$8.1 billion

Significant Investors

New Enterprise Associates, Google, Novo Holdings, Franklin Templeton Investments

Company Traction

As of June 2023, Tempus reported 50%+ of all Academic Medical Centers in the US are connected to Tempus, 40%+ of oncologists in the US are connected to Tempus through sequencing, clinical trial matching and research-enabled partnerships, and 90% of the top 20 pharma oncology companies partner with Tempus.

As of June 2023, Tempus reported 170+ biopharma partnerships, 6 million+ de-identified research records to power scientific discovery to improve patient outcomes, 20,000+ patients identified for potential enrollment into clinical trials in its network, and 100+ petabytes of data.

In March 2023, Tempus closed three major pharma contracts with Pfizer, GSK, and AstraZeneca, representing ~$700 million in revenue over the next few years.

Leadership Team

Eric Lefkofsky: Founder & CEO of Tempus. Former Co-Founder & Chairman of Groupon.

Christina Antoniou: SVP, Head of Corporate Development at Tempus. Former VP, Head of Integration at Medidata Solutions.

Terron Bruner: Chief Commercial Officer at Tempus. Former Senior Sales Leader at AWS.

Ryan Fukushima: Chief Operating Officer at Tempus. Co-Founder & CEO of Pathos.

Kate Sasser: Chief Scientific Officer at Tempus. Former SVP, Global Head of Translational Research, Precision Medicine, and R&D Operations at Genmab.

Press

Fierce Healthcare (March 2, 2023): Precision medicine company Tempus inks 3rd major pharma deal, securing nearly $1B revenue boost

Crunchbase News (October 20, 2022): Tempus Raises $275M To Combat Three Of Drugmaking’s Biggest Challenges

Fierce Healthcare (December 11, 2020): Precision medicine company Tempus lands $200M to expand into infectious diseases, mental health

Tempus